An NF2 mother finds a platform on the forefront of rare disease research

UpdatedOctober 13, 2020 · 3 minute read

After Lisa’s daughter, Jessica, was officially diagnosed with NF2, she knew she would have to be her biggest fighter. Joining AllStripes was Lisa’s way to take control and make an impact for NF2 research.

Written by Catherine Cooke Lisa

A common thread we see with parents to children with rare diseases is that they won’t take no for an answer. Lisa, mother to Jessica, “knew in [her] heart that there was something more sinister going on, when doctors underplayed her daughter’s symptoms.

It began when Jessica developed a paralysis of her 3rd cranial nerve causing a droopy eye. From there, she developed migraines that turned into seizures at the young age of 7 years old. Their journey became what is typical of those seeking a rare disease diagnosis: “It was a process of elimination. One by one we kept ticking things off the list.”

After doing her own exhaustive research, Lisa and her husband suggested that it may be Neurofibromatosis 2 (NF2), but “but the doctor said she didn’t show those symptoms. So we pushed for answers.”

They were eventually granted funding for expensive genetic whole exome sequencing, and their suspicions were confirmed: Jessica was diagnosed with NF2.

NF2 is “a genetic disorder that causes benign tumors to grow on nerves particularly affecting the brain and spine. It’s debilitating. One by one, these tumors destroy a person’s abilities and senses. They lose their functions to the point that they become debilitated. They can become deaf, blind, immobile. Eventually, in severe cases it can lead to death.”

With the diagnosis, everything changed overnight. Doctors ran more scans and discovered that her body was riddled with tumors. “They never found the tumors before because they were looking in the wrong place. It was shocking that she had so much wrong with her,” Lisa remembers.

“It was like a double edged sword,” Lisa reflects. “It was heartbreaking but empowering because we could now fight. I knew I would always be her biggest advocate. No one will fight as hard for your child as their parents.”

In the journey to find a treatment and cure for her daughter, Lisa has been searching for others who share her same motivation. That’s when she found AllStripes, a company that is on the forefront of fueling better, faster research for rare diseases. As an AllStripes user, you can store all your medical information in a centralized place that can also be anonymously accessed by rare disease researchers.

“I knew power would be knowledge,” Lisa explains about why she uses AllStripes. “As soon as I had the genetic results, I wanted to get it out to anyone who was willing to listen. I wanted a platform that would help share the information to help accelerate the research, which will help find a cure.”

She believes AllStripes helps address a big problem with the current rare disease research model: “Clinicians tend to not share information with one another. It’s hard for researchers to do what they need to do. It’s really up to patients, families, and advocates to provide this information so that doctors can help us.”

Despite all of the difficulties she faced living with a rare disease, Jessica, now 11 years old, is still “One of the happiest children you will ever meet. She is so energetic and has so much love for life. She’s the most caring nurturing person you will ever meet. She has this capacity to love so much.”

Lisa is afraid of what will happen during Jessica’s teenage years, as hormones can exacerbate NF2 tumor growth, but for now she is focused on telling herself “to stay strong. Accept the things I cannot change. Have the courage to fight for the things I can change and to never give up.”

And we all know that rare disease parents are some of the strongest fighters out there!

Share Lisa’s story today. If you are the parent of a child with NF2 and are interested in contributing to research from home learn more here.

Originally posted at October 13, 2020

Previous articleA PSP Wish List:…

Next articleEnsuring High-Quality Data for…

Back to blog